HIV epidemiology, prevention, treatment, and implementation strategies for public health
- PMID: 38043552
- DOI: 10.1016/S0140-6736(23)01381-8
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Abstract
The global HIV response has made tremendous progress but is entering a new phase with additional challenges. Scientific innovations have led to multiple safe, effective, and durable options for treatment and prevention, and long-acting formulations for 2-monthly and 6-monthly dosing are becoming available with even longer dosing intervals possible on the horizon. The scientific agenda for HIV cure and remission strategies is moving forward but faces uncertain thresholds for success and acceptability. Nonetheless, innovations in prevention and treatment have often failed to reach large segments of the global population (eg, key and marginalised populations), and these major disparities in access and uptake at multiple levels have caused progress to fall short of their potential to affect public health. Moving forward, sharper epidemiologic tools based on longitudinal, person-centred data are needed to more accurately characterise remaining gaps and guide continued progress against the HIV epidemic. We should also increase prioritisation of strategies that address socio-behavioural challenges and can lead to effective and equitable implementation of existing interventions with high levels of quality that better match individual needs. We review HIV epidemiologic trends; advances in HIV prevention, treatment, and care delivery; and discuss emerging challenges for ending the HIV epidemic over the next decade that are relevant for general practitioners and others involved in HIV care.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests EHG receives educational grants from ViiV Healthcare outside the submitted work. AHS receives grants to her institution from ViiV Healthcare and Gilead Sciences outside the submitted work. CI has received conference support and research grants from Gilead Sciences outside the submitted work. FV receives drug donations from ViiV Healthcare, Merck, Johnson & Johnson, and Gilead Sciences for investigator-led clinical studies. FV's unit perfoms investigator-led studies with the financial support of Merck, Johnson & Johnson, and ViiV Healthcare, and is performing commercial drug studies for Merck. FV's unit performs evaluations of diagnostic devices for multiple biotech companies. Individually, FV receives honoraria for educational talks and advisory board membership for Gilead, ViiV, Mylan/Viatris, Merck, Adcock-Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, and Virology Education. AM and RKJT declare no competing interests.
Comment in
-
The battle against paediatric HIV is far from over.Lancet. 2024 Aug 10;404(10452):522. doi: 10.1016/S0140-6736(24)01172-3. Lancet. 2024. PMID: 39127472 No abstract available.
-
The battle against paediatric HIV is far from over - Authors' reply.Lancet. 2024 Aug 10;404(10452):522-523. doi: 10.1016/S0140-6736(24)01173-5. Lancet. 2024. PMID: 39127473 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical